BACKGROUND & AIMS: HBV infection may reactivate in the setting of immunosuppression, although the frequency and consequences of HBV reactivation are not well known. We report 6 patients who experienced loss of serologic markers of hepatitis B immunity and reappearance of HBsAg in the serum as a result of a variety of acquired immune deficiencies. METHODS: Between 2000 and 2005, six patients with reactivation of hepatitis B were seen in consultation by the Liver Diseases Branch at the Clinical Center, National Institutes of Health. The course and outcome of these 6 patients were reviewed. RESULTS: All 6 patients developed reappearance of HBsAg and evidence of active liver disease after stem cell transplantation (n = 4), immunosuppressive therapy (n = 1), or change in human immunodeficiency virus antiretroviral regimen (n = 1), despite having antibody to HBsAg (anti-HBs) or antibody to hepatitis B core antigen (anti-HBc) without HBsAg before. All 6 patients developed chronic hepatitis B, 2 patients transmitted hepatitis B to their spouses, and 1 patient developed cirrhosis. The diagnosis of hepatitis B reactivation was frequently missed or delayed and often required interruption of the therapy for the underlying condition. None of the patients received antiviral prophylaxis against HBV reactivation. CONCLUSIONS: Serologic evidence of recovery from hepatitis B infection does not preclude its reactivation after immunosuppression. Screening for serologic evidence of hepatitis B and prophylaxis of those with positive results by using nucleoside analogue antiviral therapy should be provided to individuals in whom immunosuppressive therapy is planned.
BACKGROUND & AIMS:HBV infection may reactivate in the setting of immunosuppression, although the frequency and consequences of HBV reactivation are not well known. We report 6 patients who experienced loss of serologic markers of hepatitis B immunity and reappearance of HBsAg in the serum as a result of a variety of acquired immune deficiencies. METHODS: Between 2000 and 2005, six patients with reactivation of hepatitis B were seen in consultation by the Liver Diseases Branch at the Clinical Center, National Institutes of Health. The course and outcome of these 6 patients were reviewed. RESULTS: All 6 patients developed reappearance of HBsAg and evidence of active liver disease after stem cell transplantation (n = 4), immunosuppressive therapy (n = 1), or change in human immunodeficiency virus antiretroviral regimen (n = 1), despite having antibody to HBsAg (anti-HBs) or antibody to hepatitis B core antigen (anti-HBc) without HBsAg before. All 6 patients developed chronic hepatitis B, 2 patients transmitted hepatitis B to their spouses, and 1 patient developed cirrhosis. The diagnosis of hepatitis B reactivation was frequently missed or delayed and often required interruption of the therapy for the underlying condition. None of the patients received antiviral prophylaxis against HBV reactivation. CONCLUSIONS: Serologic evidence of recovery from hepatitis B infection does not preclude its reactivation after immunosuppression. Screening for serologic evidence of hepatitis B and prophylaxis of those with positive results by using nucleoside analogue antiviral therapy should be provided to individuals in whom immunosuppressive therapy is planned.
Authors: P Seth; A A Alrajhi; I Kagevi; M A Chaudhary; E Colcol; E Sahovic; M Aljurf; M Gyger Journal: Bone Marrow Transplant Date: 2002-08 Impact factor: 5.483
Authors: Pedro P Joya-Vazquez; Forrest S Dodson; Igor Dvorchik; Edward Gray; Amy Chesky; Anthony J Demetris; Obaid Shakil; John J Fung; Hugo E Vargas Journal: Transplantation Date: 2002-05-27 Impact factor: 4.939
Authors: Jose R Nery; Caio Nery-Avila; K Rajender Reddy; Robert Cirocco; Deborah Weppler; David M Levi; Seigo Nishida; Juan Madariaga; Tomoaki Kato; Phillip Ruiz; Eugene Schiff; Andreas G Tzakis Journal: Transplantation Date: 2003-04-27 Impact factor: 4.939
Authors: S Goyama; Y Kanda; Y Nannya; M Kawazu; M Takeshita; M Niino; Y Komeno; T Nakamoto; M Kurokawa; S Tsujino; S Ogawa; K Aoki; S Chiba; T Motokura; Y Shiratori; H Hirai Journal: Leuk Lymphoma Date: 2002-11
Authors: Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba Journal: Support Care Cancer Date: 2012-08-30 Impact factor: 3.603
Authors: Jonathan Ramirez; Anupama Thadareddy Duddempudi; Moazzam M Sana; Syed S Hasan; Mario de Los Santos; Juhee Song; Ying Fang-Hollingsworth; Sandeep S Gupta; Dawn M Sears Journal: Proc (Bayl Univ Med Cent) Date: 2015-10